The use of tumour necrosis factor (TNF) inhibitors in the treatment of ADA2 deficiency has significantly improved patient care; however, the response to therapy is not always favourable, especially in cases with immunodeficiency and haematological manifestations. The gene discussed is ADA2; the disease is immune system disorder.